Device Vascular Access Devices

Bd Nexiva Diffusics

Payments companies reported to CMS as associated with Bd Nexiva Diffusics. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2,038associated payments (2023-2025)
48clinicians with associated payments
2companies reporting

By year

2023 $116
2024 $1,069
2025 $852

Payments reported as associated with Bd Nexiva Diffusics, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Cardiovascular Disease $476
Vascular & Interventional Radiology $209
Family $195
Critical Care Medicine (Clinical Nurse Specialist) $158
Acute Care (Nurse Practitioner) $123
Nurse Anesthetist, Certified Registered $102

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Bd Nexiva Diffusics

These are the largest totals companies reported as associated with Bd Nexiva Diffusics. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Wesley O'Neal Greensboro, NC Cardiovascular Disease $440.95
Mary Jo Kelly Seattle, WA Critical Care Medicine (Clinical Nurse Specialist) $158.00
Michael Korona Huntington, WV Vascular & Interventional Radiology $119.78
Barbara Nickel Kimball, NE $84.93
John Ledonne Baltimore, MD Surgery $67.57
Jacob Albert Palm Harbor, FL Family Medicine $58.59
Elizabeth Budnik Park Ridge, IL Pediatric Emergency Medicine (Pediatrics) $53.70
Amanda March Seattle, WA Neurology With Special Qualifications In Child Neurology $53.69
Laurie Deruosi Wesley Chapel, FL Family $42.46
Shannon Moulton Tampa, FL Acute Care (Nurse Practitioner) $42.46

Prescribed Bd Nexiva Diffusics?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.